Abstract
Bone scintigraphy (SO) with bisphosphate labeled with 99mTc remains indicated in the guidelines for the detection of bone metastases before treatment of intermediate risk and high risks of recurrence prostate cancers (PC). SO remains also indicated in the evaluation of response to treatment of metastatic bone disease. Its main advantages are its availability, as it is performed routinely in all nuclear medicine centers in France, and very high performances, since whole-body Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) hybrid tomoscintigraphy almost systematically completes whole-body scanning. We propose in this article to review this technique at all clinical stages of CP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
